{"id":72249,"date":"2026-08-11T12:09:37","date_gmt":"2026-08-11T04:09:37","guid":{"rendered":"https:\/\/flcube.com\/?p=72249"},"modified":"2026-08-11T12:09:38","modified_gmt":"2026-08-11T04:09:38","slug":"crystalo-biopharma-signs-collaboration-and-licensing-deal-with-almirall-for-ai-driven-skin-disease-drug-discovery-worth-up-to-e254-5-million","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=72249","title":{"rendered":"CrystalO Biopharma Signs Collaboration and Licensing Deal With Almirall for AI\u2011Driven Skin Disease Drug Discovery, Worth Up to \u20ac254.5 Million"},"content":{"rendered":"\n

CrystalO Biopharma Co., Ltd.<\/strong> announced that it has entered into a collaboration and licensing agreement<\/strong> with Almirall, S.A. (BME: ALM<\/a>)<\/strong>, a global biopharmaceutical company focused on medical dermatology, to jointly develop innovative drug candidates for skin diseases<\/strong>. The deal is worth up to approximately \u20ac254.5 million<\/strong> in upfront, milestone and royalty payments.<\/p>\n\n\n\n

Deal Overview<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Parties<\/strong><\/td>CrystalO Biopharma Co., Ltd. \u00d7 Almirall, S.A. (BME: ALM)<\/td><\/tr>
Deal Type<\/strong><\/td>Collaboration and licensing agreement<\/td><\/tr>
Focus<\/strong><\/td>Innovative drug candidates for skin diseases<\/td><\/tr>
Discovery Platform<\/strong><\/td>CrystalO’s proprietary AI\u2011 and structural biology\u2011driven drug discovery platform<\/td><\/tr>
Total Deal Value<\/strong><\/td>Up to ~\u20ac254.5 million (upfront + milestones + royalties)<\/td><\/tr>
Announcement Date<\/strong><\/td>10 Aug 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Division of Responsibilities<\/h2>\n\n\n\n
Stage<\/th>CrystalO Biopharma<\/th>Almirall<\/th><\/tr><\/thead>
Compound Discovery<\/strong><\/td>Leads via AI\u2011 and structural biology\u2011driven platform<\/td>\u2013<\/td><\/tr>
Optimization & IND\u2011Enabling Studies<\/strong><\/td>Oversees execution<\/td>\u2013<\/td><\/tr>
Early Clinical Development<\/strong><\/td>Leads up to clinical proof\u2011of\u2011concept (POC)<\/td>\u2013<\/td><\/tr>
Post\u2011POC Development, Manufacturing, Commercialization (Global ex\u2011Mainland China)<\/strong><\/td>\u2013<\/td>Exclusive rights<\/td><\/tr>
Mainland China Rights<\/strong><\/td>Retains exclusive development and commercialization rights post\u2011POC<\/td>\u2013<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Financial Terms<\/h2>\n\n\n\n
Component<\/th>Direction<\/th>Detail<\/th><\/tr><\/thead>
Upfront Payment<\/strong><\/td>Almirall \u2192 CrystalO<\/td>Paid at deal signing<\/td><\/tr>
Milestone Payments<\/strong><\/td>Almirall \u2192 CrystalO<\/td>Based on R&D, regulatory and commercial successes<\/td><\/tr>
Tiered Royalties (Global ex\u2011Mainland China)<\/strong><\/td>Almirall \u2192 CrystalO<\/td>On future net sales<\/td><\/tr>
Total Potential Value<\/strong><\/td>Almirall \u2192 CrystalO<\/td>Up to approximately \u20ac254.5 million<\/strong><\/td><\/tr>
Tiered Royalties (Mainland China)<\/strong><\/td>CrystalO \u2192 Almirall<\/td>Based on future product sales in Mainland China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Rationale & Market Impact<\/h2>\n\n\n\n